Sequoia Financial Advisors LLC Buys 31,756 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Posted by George Bondi on Jul 13th, 2026

Sequoia Financial Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 23.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 169,700 shares of the company’s stock after acquiring an additional 31,756 shares during the period. Sequoia Financial Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $5,111,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in TEVA. Aster Capital Management DIFC Ltd acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $25,000. Allworth Financial LP lifted its stake in Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares in the last quarter. Grove Bank & Trust boosted its position in Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after acquiring an additional 750 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after acquiring an additional 345 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Teva Pharmaceutical Industries by 567.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock worth $42,000 after acquiring an additional 1,134 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on TEVA. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Truist Financial upped their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Barclays increased their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Piper Sandler reiterated an “overweight” rating and set a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Finally, Bank of America increased their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 9th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average target price of $41.78.

View Our Latest Report on TEVA

Insider Transactions at Teva Pharmaceutical Industries

In other news, CAO Amir Weiss sold 10,679 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the sale, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at $720,576. This trade represents a 34.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the transaction, the executive vice president directly owned 55,755 shares in the company, valued at $1,973,727. The trade was a 34.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 465,931 shares of company stock valued at $16,332,989. Company insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.4%

Shares of TEVA stock opened at $32.82 on Monday. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The firm’s 50-day moving average is $34.14 and its 200-day moving average is $32.69. The stock has a market cap of $37.74 billion, a price-to-earnings ratio of 24.68, a PEG ratio of 4.02 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $3.98 billion during the quarter. Sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current year.

About Teva Pharmaceutical Industries

(Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.